HK1206057A1 - Mammalian cell culture - Google Patents

Mammalian cell culture

Info

Publication number
HK1206057A1
HK1206057A1 HK15106530.7A HK15106530A HK1206057A1 HK 1206057 A1 HK1206057 A1 HK 1206057A1 HK 15106530 A HK15106530 A HK 15106530A HK 1206057 A1 HK1206057 A1 HK 1206057A1
Authority
HK
Hong Kong
Prior art keywords
cell culture
mammalian cell
mammalian
culture
cell
Prior art date
Application number
HK15106530.7A
Other languages
English (en)
Chinese (zh)
Inventor
Brian D Follstad
Rebecca E Mccoy
Arvia E Morris
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1206057A1 publication Critical patent/HK1206057A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15106530.7A 2011-07-01 2014-10-20 Mammalian cell culture HK1206057A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
HK1206057A1 true HK1206057A1 (en) 2015-12-31

Family

ID=46579326

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15106530.7A HK1206057A1 (en) 2011-07-01 2014-10-20 Mammalian cell culture
HK14110449A HK1197081A1 (en) 2011-07-01 2014-10-20 Mammalian cell culture

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14110449A HK1197081A1 (en) 2011-07-01 2014-10-20 Mammalian cell culture

Country Status (24)

Country Link
US (7) US11292829B2 (fr)
EP (2) EP2837680B1 (fr)
JP (1) JP5897708B2 (fr)
KR (6) KR101857380B1 (fr)
CN (2) CN103827292B (fr)
AU (5) AU2012279230B2 (fr)
BR (2) BR112013033730B1 (fr)
CA (2) CA2952347A1 (fr)
CL (2) CL2013003792A1 (fr)
CY (2) CY1118863T1 (fr)
DK (2) DK2726600T3 (fr)
EA (1) EA039023B1 (fr)
ES (2) ES2625045T3 (fr)
HK (2) HK1206057A1 (fr)
HU (2) HUE049119T2 (fr)
IL (6) IL315908A (fr)
LT (2) LT2726600T (fr)
MX (1) MX351974B (fr)
PL (2) PL2726600T3 (fr)
PT (2) PT2837680T (fr)
SG (1) SG10201702537RA (fr)
SI (2) SI2837680T1 (fr)
WO (1) WO2013006479A2 (fr)
ZA (1) ZA201309372B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2910619A1 (fr) 2006-09-13 2008-03-20 Abbvie Inc. Ameliorations a la culture de cellules
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
US11292829B2 (en) * 2011-07-01 2022-04-05 Amgen Inc. Mammalian cell culture
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
MX2014004728A (es) 2011-10-18 2015-05-15 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con cloruro de sodio.
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
MX2015000337A (es) 2012-07-09 2015-09-25 Coherus Biosciences Inc Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN110051823A (zh) 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
US20140199728A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
EP2830651A4 (fr) 2013-03-12 2015-09-02 Abbvie Inc Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
TWI625390B (zh) 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2978498B1 (fr) * 2013-03-26 2019-07-03 Coherus Biosciences, Inc. Procédé de production de protéine
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
EP3063287A1 (fr) * 2013-10-31 2016-09-07 Amgen Inc. Utilisation de monensine pour réguler la glycosylation de protéines de recombinaison
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
WO2015095809A1 (fr) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Utilisation de cultures de semences sous perfusion pour améliorer la capacité de production en alimentation programmée de produits biopharmaceutiques et la qualité des produits
WO2015105609A1 (fr) 2014-01-13 2015-07-16 Amgen Inc. Régulation du métabolisme de l'ornithine pour manipuler la teneur en glycoformes à haute teneur en mannose de protéines de recombinaison
US10047141B2 (en) 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
FI3926051T3 (fi) 2014-06-04 2024-06-18 Amgen Inc Menetelmiä nisäkässoluviljelmien keräämiseksi
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI707949B (zh) * 2014-06-09 2020-10-21 美商健臻公司 種子罐培養法（ｓｅｅｄ ｔｒａｉｎ ｐｒｏｃｅｓｓｅｓ）及其用途
JP6530171B2 (ja) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 培養産生物の回収方法
ES2784503T3 (es) * 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
WO2017120359A1 (fr) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Réduction des espèces de masse moléculaire élevée, des espèces de charge acide, et des fragments dans une composition d'anticorps monoclonaux
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
JP6974341B2 (ja) * 2016-03-02 2021-12-01 ロンザ リミテッドLonza Limited 改善された発酵プロセス
US20200377918A1 (en) * 2017-03-31 2020-12-03 Boehringer Ingelheim International Gmbh Perfusion medium
US11702628B2 (en) 2017-03-31 2023-07-18 Boehringer Ingelheim International Gmbh Perfusion medium for culturing mammalian cells and reducing cell bleed in a perfusion cell culture
EP3639171A4 (fr) * 2017-06-16 2021-07-28 Cytiva Sweden AB Procédé de prédiction du résultat et de modélisation d'un processus dans un bioréacteur
MX2020001490A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
IL273549B2 (en) 2017-10-06 2023-10-01 Lonza Ag Automated control of cell culture using Raman spectroscopy
ES2919850T3 (es) 2017-10-16 2022-07-28 Regeneron Pharma Procedimientos de perfusión
WO2019113557A1 (fr) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Procédé de production d'une compositions de lymphocytes t modifiés
CN112074537A (zh) 2018-05-01 2020-12-11 美国安进公司 具有经调节的聚糖谱的抗体
PL3818078T3 (pl) * 2018-07-03 2024-04-29 Bristol-Myers Squibb Company Metody produkcji białek rekombinowanych
US11680239B2 (en) 2018-12-31 2023-06-20 Repligen Corporation Filter for mammalian cell culture perfusion and clarification with hydrophobic hollow fiber
KR20220066970A (ko) * 2019-09-27 2022-05-24 베링거 인겔하임 인터내셔날 게엠베하 농축 관류식 배지
WO2022036275A2 (fr) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Procédé de fabrication de protéine
WO2022047108A1 (fr) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Stratégies d'alimentation d'asparagine pour améliorer la performance de culture cellulaire et atténuer des variants de séquence d'asparagine
KR20230073270A (ko) * 2020-09-22 2023-05-25 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 생산 방법
CN114574430A (zh) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 一种Expi293F细胞培养方法
CN115287251A (zh) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 间歇性灌流联合分批流加培养
AR130375A1 (es) 2022-09-06 2024-12-04 Amgen Inc Métodos de cultivo de celulas por perfusión controlada
TW202421771A (zh) 2022-09-16 2024-06-01 美商安進公司 從灌注培養物收穫產物的方法
WO2024220354A1 (fr) * 2023-04-15 2024-10-24 Puerto Rico Science Technology & Research Trust Procédés de production de glycoprotéines d'enveloppe du vih-1 et microparticules de guanosine associées
CN116790483B (zh) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 一种cho细胞无血清培养基及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (fr) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
ATE503013T1 (de) 1995-06-29 2011-04-15 Immunex Corp Cytokin welches apoptose induziert
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP2221361A3 (fr) 1996-08-30 2011-02-09 Life Technologies Corporation Méthode de production d'un polypeptide in vitro dans une cellule de mammifère dans un milieu de culture sans sérum and sans protéines
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (fr) 1999-11-17 2001-05-25 Immunex Corporation Activateur du recepteur de nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2480121C (fr) 2002-03-27 2012-02-28 Immunex Corporation Procedes d'augmentation de la production de polypeptides
PT1720972E (pt) * 2004-03-05 2014-04-07 Dsm Ip Assets Bv Processo para cultura de células por perfusão contínua e fluxo alternativo tangencial
CN1332024C (zh) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 一种海绵细胞的微载体三维培养方法
US7722915B2 (en) 2004-07-07 2010-05-25 Coloplast A/S Preparation of hydrophillic coatings utilizing a 1,3-dioxolane compound
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
CA2585547A1 (fr) * 2004-10-29 2006-05-11 Centocor, Inc. Compositions de milieux chimiquement definis
SI2267024T1 (sl) * 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
ES2625066T3 (es) 2006-07-14 2017-07-18 Patheon Holdings I B.V. Proceso mejorado para el cultivo de células
US20080206819A1 (en) * 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
ES2538986T3 (es) 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
EP3327132A3 (fr) 2007-08-09 2018-07-18 Wyeth LLC Utilisation de la perfusion pour améliorer la production d'une culture cellulaire en mode semi-continu dans des bioréacteurs
EP2326720B1 (fr) 2008-09-15 2018-03-21 F. Hoffmann-La Roche AG Compositions et procédés pour réguler l'osmolarité cellulaire
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
BR122021005965B1 (pt) 2009-07-31 2022-01-25 Baxalta Incorporated Método para produzir uma composição de desintegrina e metaloproteinase com motivo trombospondina (adamts)
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
PL2501822T3 (pl) 2009-11-17 2017-12-29 E. R. Squibb & Sons, L.L.C. Sposoby zwiększenia produkcji białek
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
MX348637B (es) * 2010-11-01 2017-06-22 Symphogen As Anticuerpos y composiciones anti-her3.
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US11292829B2 (en) * 2011-07-01 2022-04-05 Amgen Inc. Mammalian cell culture
TWI625390B (zh) 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
EP3063287A1 (fr) 2013-10-31 2016-09-07 Amgen Inc. Utilisation de monensine pour réguler la glycosylation de protéines de recombinaison
EP3377613A1 (fr) * 2015-11-17 2018-09-26 Pfizer Inc Milieux et procédés de fermentation pour la production de polysaccharides dans une culture de cellules bactériennes

Also Published As

Publication number Publication date
CN107988166A (zh) 2018-05-04
AU2018203972B2 (en) 2020-09-17
CA2838695A1 (fr) 2013-01-10
EP2837680B1 (fr) 2020-02-26
US11673941B2 (en) 2023-06-13
DK2726600T3 (en) 2017-05-15
KR101857380B1 (ko) 2018-05-11
KR20160075814A (ko) 2016-06-29
US20200407427A1 (en) 2020-12-31
US11634476B2 (en) 2023-04-25
US11685772B2 (en) 2023-06-27
LT2726600T (lt) 2017-05-25
CL2016001190A1 (es) 2017-06-09
IL297998A (en) 2023-01-01
US20140255993A1 (en) 2014-09-11
WO2013006479A3 (fr) 2013-03-28
CA2952347A1 (fr) 2013-01-10
BR112013033730B1 (pt) 2022-01-25
KR102558247B1 (ko) 2023-07-24
IL288509B2 (en) 2023-04-01
KR20240005106A (ko) 2024-01-11
ES2788132T3 (es) 2020-10-20
KR20220021008A (ko) 2022-02-21
PL2837680T3 (pl) 2020-08-10
KR20200051046A (ko) 2020-05-12
KR20230114317A (ko) 2023-08-01
KR20180050433A (ko) 2018-05-14
AU2020281075A1 (en) 2021-01-07
CN103827292A (zh) 2014-05-28
AU2020281075B2 (en) 2022-12-22
EP2837680A1 (fr) 2015-02-18
ES2625045T3 (es) 2017-07-18
AU2023201127A1 (en) 2023-03-30
HK1197081A1 (en) 2015-01-02
IL310968B1 (en) 2024-11-01
ZA201309372B (en) 2014-08-27
CN107988166B (zh) 2022-03-15
KR20140031375A (ko) 2014-03-12
IL310968A (en) 2024-04-01
EA201391826A1 (ru) 2014-04-30
EA039023B1 (ru) 2021-11-23
US11827692B2 (en) 2023-11-28
MX2013014937A (es) 2014-04-16
US20220185869A1 (en) 2022-06-16
KR102108663B1 (ko) 2020-05-07
BR122021007265B1 (pt) 2022-02-22
IL278430B (en) 2022-01-01
BR112013033730A2 (pt) 2017-01-31
DK2837680T3 (da) 2020-04-27
US11292829B2 (en) 2022-04-05
US20230129523A1 (en) 2023-04-27
AU2012279230A1 (en) 2014-01-09
AU2016244255A1 (en) 2016-10-27
US20230227535A1 (en) 2023-07-20
CY1118863T1 (el) 2018-01-10
US20210061888A1 (en) 2021-03-04
IL297998B2 (en) 2024-07-01
HUE033279T2 (en) 2017-11-28
IL229803B (en) 2020-11-30
AU2012279230B2 (en) 2016-08-18
SG10201702537RA (en) 2017-04-27
JP2014520534A (ja) 2014-08-25
KR102358951B1 (ko) 2022-02-08
AU2018203972A1 (en) 2018-06-21
WO2013006479A2 (fr) 2013-01-10
PT2726600T (pt) 2017-04-24
PL2726600T3 (pl) 2017-08-31
LT2837680T (lt) 2020-07-10
EP2726600B1 (fr) 2017-02-15
SI2837680T1 (sl) 2020-07-31
JP5897708B2 (ja) 2016-03-30
US20230117598A1 (en) 2023-04-20
MX351974B (es) 2017-11-06
CN103827292B (zh) 2018-01-26
SI2726600T1 (sl) 2017-07-31
CL2013003792A1 (es) 2014-07-25
CY1123146T1 (el) 2021-12-31
HUE049119T2 (hu) 2020-09-28
EP2726600A2 (fr) 2014-05-07
IL288509A (en) 2022-01-01
CA2838695C (fr) 2017-02-14
IL297998B1 (en) 2024-03-01
IL288509B (en) 2022-12-01
KR101662412B1 (ko) 2016-10-04
PT2837680T (pt) 2020-04-17
IL315908A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
IL288509A (en) Mammalian cell culture
SG10201601434RA (en) Cell Culture System
EP2729561A4 (fr) Procédé de culture cellulaire
HK1183057A1 (en) Cell culture insert
IL226971B (en) Cell culture medium
SG11201503579RA (en) Cell culture med
EP3144319B8 (fr) Composition de culture cellulaire comprenant laminine-521
SG11201500417PA (en) Cell culture
EP2796537A4 (fr) Support de culture cellulaire
HUE058968T2 (hu) Sejtkultúra tenyésztésére szolgáló eszköz
GB201211873D0 (en) Cell culture
GB201114752D0 (en) Cell staining process
GB201007863D0 (en) Bioreactor for cell culture
GB201120446D0 (en) Mammalian cell transformation method
GB201007855D0 (en) Bioreactor for the culture of cells
GB201016327D0 (en) Mammalian cell preservation methods
GB201000999D0 (en) Mammalian cell preservation methods
AU2011903899A0 (en) Cell culture & expansion
PL393251A1 (pl) Mikroukład do hodowli komórkowej
GB201115343D0 (en) Mammalian Haploid embryonic stem cells
GB201110577D0 (en) Culturing microorganisms
GB201020075D0 (en) Mammalian cell transformation method
GB201106652D0 (en) Mammalian model